Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Amgen Has More Good News. What Is Going on with the CRISPR Gene Editing Firms?

May 1, 2018 0

A couple of days following the news that the Committee for Medicinal Products for Human Use (CHMP) …

AveXis Drug’s Data for Spinal Muscular Atrophy Highlights Gene Therapy

April 30, 2018 0

The Week in Review #21 Part 2 THE MARKET (2) - Our remarks in the past Week …

ImmunoGen Stock Flied on Ovarian Cancer Drug News

April 27, 2018 0

The Independent Data Monitoring Committee (IDMC) decided that ImmunoGen (IMGN) Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent …

Nektar and Takeda Explore Immunotherapy Combinations for Multiple Cancers. Sangamo Is Financing Through Public Offering

April 26, 2018 0

NEKTAR Nektar Therapeutics (NKTR) and Takeda Pharmaceutical (TKPYY) are collaborating to evaluate Nektar’s investigational medicine, NKTR-214, with Takeda’s investigational medicine, TAK-659, as a potential …

Alnylam’s RNAi Product Patisiran Has More Positive News

April 25, 2018 0

The Market The Stock Market is Still under pressure, which is frightening common investors, pressuring them …

The Biotech Revolution is Alive and Speeding

April 24, 2018 0

The Week in Review #21 Part 1 THE MARKET - Like symphonic orchestras that bring to the listeners’ …

Real Breakthroughs

April 17, 2018 0

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary …

Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial

April 12, 2018 0

Bellicum Pharmaceuticals (BLCM): The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on studies of BPX-501 in …

Illumina’s Contribution to Practicing Precision Medicine

April 11, 2018 0

When we reiterated that Illumina (ILMN) is the engine of the biotechnology evolution we meant it. We have …

Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

April 10, 2018 0

NOVARTIS TO ACQUIRE AVEXIS A few months ago, Novartis (NVS) CEO agreed to cash out of the company’s …

Let’s Go Shopping

April 6, 2018 0

In today’s news, Incyte’s (INCY) immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda® did not …

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

April 5, 2018 0

THE BIOTECH EVOLUTION: AN UNPARALLELED SPEED The Tremendous Regret Investors Will Feel If They Sell the Best of the Best Biotechnology Firms …

Why Investors Caused a Selloff of Alnylam’s Stock

April 2, 2018 0

Alnylam (ALN) is probably experiencing a stock selloff following the announcement of successful results from Pfizer’s (PFE) drug tafamidis. …

News from PTC Therapeutics, Celgene and Heron Therapeutics

March 29, 2018 0

IN THE NEWS PTC THERAPEUTICS PTC Therapeutics (PTCT) stock, which dipped yesterday, probably on news announcing a …

An Erroneous Interpretation of an Outstanding Achievement in CRISPR Gene Editing

March 28, 2018 0

A False Reason for Unwarranted Selling of CRISPR/Cas9 Gene Editing Shares CRISPRs are bacterial immune systems …

Bull or Bear

March 26, 2018 0

The Week in Review #20 THE MARKET - My friend asked: “Are you scared?” “Of what?” …

Exelixis’ and Array’s Enchanting News

March 23, 2018 0

Exelixis: Delightful Overseas Cabozantinib News Ipsen (EPA:IPN) announced that the Committee for Medicinal Products for Human Use …

Regeneron Discovers the Therapeutic Target for Non-Viral Chronic Liver Diseases. Alnylam is Assigned to Discover and Create the Targeted RNAi Therapeutic

March 22, 2018 0

Regeneron (REGN) and Alnylam (ALNY) announced a collaborative agreement aimed at identifying RNAi therapeutics for the chronic liver disease …

Roche Checkpoint Inhibitor Conquers Squamous Non-Small-Cell Lung Cancer. See Also: Some Insight on Immunotherapy and More

March 21, 2018 0

In spite of their successes, Immuno-oncology products, which we still like to call immunotherapy for several …

Arena Pharmaceuticals: Positive Results on Ulcerative Colitis

March 20, 2018 0

Arena Pharmaceuticals (ARNA) announced positive Phase 2 results from the OASIS trial for etrasimod in ulcerative colitis (UC). The Drug: Etrasimod is a …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd